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Abstract
Norovirus infection constitutes the primary cause of acute viral gastroenteritis. There are currently 
no vaccines or norovirus-specific antiviral therapeutics available for the management of norovirus 
infection. Norovirus 3C-like protease is essential for viral replication, consequently, inhibition of 
this enzyme is a fruitful avenue of investigation that may lead to the emergence of anti-norovirus 
therapeutics. We describe herein the optimization of dipeptidyl inhibitors of norovirus 3C-like 
protease using iterative SAR, X-ray crystallographic, and enzyme and cell-based studies. We also 
demonstrate herein in vivo efficacy of an inhibitor using the murine model of norovirus infection.
Introduction
Human noroviruses are the primary cause of sporadic and epidemic acute gastroenteritis in 
the US and worldwide,1–3 consequently, they constitute an important public health problem, 
as well as a potential bioterrorism threat. Although the illness is generally considered to be 
mild and self-limiting, it can incapacitate infected individuals, including military troops on 
ships or war zones during the symptomatic phase.4 Noroviruses are very stable in the 
environment and refractory to many common disinfectants, with only a few virions required 
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to initiate virus infection and shedding, which could be a source for further contamination. 
Therefore, norovirus outbreaks are hard to contain using routine sanitation, and even 
implementation of aggressive sanitary measures often fails to prevent subsequent 
outbreaks.5–6 The problem is further compounded by the current dearth of diagnostics, 
effective vaccines, and norovirus-specific antiviral therapeutics and/or prophylactics.7–9
Human noroviruses are single-stranded, positive sense RNA viruses belonging to the 
Caliciviridae family.10 Genogroups I, II and IV of the six genogroups (GI-GVI) in the genus 
Norovirus are known to infect humans. The norovirus genome (7–8 kb) consists of three 
open reading frames that encode a 200 kDa polyprotein (ORF1), a major capsid protein VP1 
(ORF2), and a small basic protein VP2 (ORF3).10–11 The mature polyprotein precursor is 
processed by a virus-encoded 3C-like protease (3CLpro) to generate six mature non-
structural proteins, including the viral protease (3CLpro or NS6Pro) and the RNA dependent 
RNA polymerase (NS7Pol).12 Co- and post-translational processing of the polyprotein by 
norovirus 3CLpro is essential for virus replication, consequently, norovirus 3CLpro has 
emerged as a potential druggable target for the discovery of anti-norovirus small molecule 
therapeutics and prophylactics.13–14
Norovirus 3CLpro is a chymotrypsin-like cysteine protease with a Cys-His-Glu catalytic 
triad and an extended binding site.11,15 The primary substrate specificity of the protease is 
for a P1 glutamine residue and a strong preference for a –D/E-F-X-L-Q-G-P-sequence (X is 
H, Q or V), corresponding to the subsites S5-S4-S3-S2-S1-S1’-S2’-, respectively.15–16 
Cleavage is at the P1-P1’ (Q–G) scissile bond. We have recently reported an array of 
norovirus inhibitors, including acyclic and cyclic sulfamide17–19 and piperazine20 
derivatives. We have also disclosed for the first time peptidyl transition state (TS) 
inhibitors,13a–e TS mimics,13f as well as macrocyclic inhibitors13g effective in enzyme and 
cell based assays. We have furthermore described the first high throughput FRET assay of 
3CLpro from GI and GII noroviruses as a screening tool for identifying potential protease 
inhibitors and have determined high resolution X-ray crystal structures of Norwalk virus 
(NV, a prototype strain of norovirus) 3CLpro in complex with peptidyl transition state 
inhibitors,13c as well as the first solution structure of the protease using high-field NMR.13h 
Finally, we have demonstrated proof-of-concept using the mouse model of murine norovirus 
(MNV) infection (vide infra).
In continuing our foray in this area, we describe herein the structure-based optimization of a 
series of dipeptidyl inhibitors of NV 3CLpro represented by structure (I) (Figure 1) using an 
array of X-ray crystallographic, structure-activity relationship, biochemical, cell-based, and 
animal studies using the mouse model of murine norovirus (MNV) infection.
Results and Discussion
Inhibitor Design Rationale
We initially focused on the design of peptidyl transition state inhibitors of NV 3CLpro that 
incorporate in their structure a recognition element (a peptidyl fragment) that is congruent 
with the known substrate specificity of the enzyme (vide supra) and a warhead (aldehyde or 
α-ketoamide), latent warhead (bisulfite adduct) or transition state mimic (α-
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hydroxyphosphonate). In the case of inhibitors incorporating an aldehyde or α-ketoamide 
functionality in their structure, interaction with the active site cysteine (Cys139) leads to the 
formation of a reversible adduct (Figure 2).17a–c
Furthermore, in previous studies we demonstrated that norovirus 3CLpro shows a strong 
preference for a P2 cyclohexylalanine and, consequently, a P2 cyclohexyl alanine residue, as 
well as a glutamine surrogate,21 were incorporated in the structures of the inhibitors. The 
key binding interactions between norovirus 3CLpro and inhibitor were revealed by 
determining the high resolution X-ray crystal structure of NV 3CLpro with bound inhibitor 
(I) (R1=cyclohexylmethyl, R2=H, X=CH(OH)SO3Na). The co-crystal structure of the 
complex showed that, under the crystallization conditions used, the bisulfite reverted to the 
precursor aldehyde which subsequently formed a tetrahedral adduct with the active site 
cysteine (Cys139) (Figure 3). Inspection of the co-crystal structure revealed opportunities 
for additional binding interactions with a more efficient use of chemical structure. 
Specifically, one such opportunity was recognized by observing that there is a particular 
stretch of residues spanning Ala159, Ala160, Thr161 and Lys162 that are within 4.0 Å from 
the benzyl ring (Figure 4). Thus, it was envisaged that the incorporation of an appropriate 
functional group into the phenyl ring could serve as a locus for the formation of a hydrogen 
bond with the Thr161 or Lys162 backbone and/or side chains, stabilizing the flexible benzyl 
segment and increasing binding affinity. The formation of a halogen bond also appeared 
plausible.22 Thus, a small focused library of compounds was synthesized to evaluate these 
hypotheses, the ultimate goal being the identification of a dipeptidyl lead candidate suitable 
for conducting preclinical studies.
Chemistry
The synthesis of compounds 13–44 is outlined in Scheme 1. Refluxing cyclohexylalanine 
methyl ester hydrochloride (or leucine methyl ester hydrochloride) with trichloromethyl 
chloroformate yielded the corresponding isocyanate which was reacted with an 
appropriately substituted benzyl alcohol to yield a carbamate adduct methyl ester that was 
hydrolyzed to the corresponding acid with lithium hydroxide in aqueous THF. Subsequent 
coupling with glutamine surrogate methyl ester hydrochloride21 afforded the desired 
dipeptidyl ester which was then reduced to the corresponding alcohol with lithium 
borohydride. Dess-Martin oxidation followed by flash chromatography purification yielded 
pure dipeptidyl aldehyde. The enantiomeric purity of the aldehyde was consistently high, 
with the amount of epimerized aldehyde ranging between 0–10%, depending on the 
structure of the dipeptidyl aldehyde. Further reaction of the aldehyde with diethyl phosphite 
in the presence of diisopropyl ethyl amine yielded the corresponding α-hydroxyphosphonate 
as a mixture of epimers.23 The corresponding bisulfite adducts were readily obtained as 
white solids by stirring the aldehydes with sodium bisulfite in an ethyl acetate/water 
mixture.24 Reaction of the aldehyde with cyclopropyl isonitrile followed by Dess-Martin 
oxidation of the α-hydroxy cyclopropyl amide yielded the desired α-ketoamides. The 
synthesized compounds are listed in Table 1.
The synthesized compounds were evaluated for their inhibitory activity against NV 3CLpro, 
as well as their anti-norovirus activity in a cell-based replicon system, as previously 
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described.13 The IC50 and ED50 values are the average of at least two determinations and are 
listed in Table 1. The enzyme selectivity of a select number of inhibitors was evaluated 
against a panel of representative proteases and the results are summarized in Table 2. The 
methodologies employed in conducting the enzyme assays and inhibition studies were as 
described previously by us13 and others.25 The in vivo efficacy of compound 16 was 
evaluated in the murine model of norovirus infection.
X-ray crystallography was used to elucidate the nature of the interaction of compound 17 
with NV 3CLpro. The X-ray crystal structure of NV 3CLpro revealed the presence of 
prominent difference electron density with the substructure of 17 that is equivalent to 
precursor aldehyde inhibitor 16 covalently bound to Cys 139. However, no electron density 
was observed for the hydroxyphosphonate group that should be present for inhibitor 17 
(Figure 5). Instead, the structure of the NV 3CLpro-ligand complex was found to correspond 
to the covalent adduct of precursor aldehyde inhibitor 16 and NV 3CLpro. In addition, the 
m-chlorobenzyl ring was partially disordered so the electron density for this region of the 
inhibitor was somewhat ambiguous. The interactions between NV 3CLpro and inhibitor 16 
are shown in Figure 6. The m-chlorophenyl ring of inhibitor 16 occupies a hydrophobic 
pocket near Ile 109 and Val 168. Van der Waals and electrostatic surface representations of 
the inhibitor and NV 3CLpro are shown in Figure 7.
Inspection of the results shown in Table 1 reveals that, in general, dipeptidyl inhibitors that 
incorporate in their structure an aldehyde or aldehyde bisulfite adduct (masked aldehyde) 
display lower ED50 values than the corresponding compounds bearing an α-
hydroxyphosphonate or α-ketoamide moiety. Furthermore, the aldehyde and aldehyde 
bisulfite adduct-derived inhibitors had comparable ED50 values. These results are consistent 
with previous studies which showed that the activity of the aldehyde bisulfite adducts 
parallels the activity of the precursor aldehydes.13d,f Other things being equal, inhibitors 
having a cyclohexyl alanine P2 residue are more potent than the corresponding t-butyl 
glycine or leucine inhibitors (compare compounds 16, 21 and 22). As revealed by the X-ray 
crystal structure (Figure 7), the cyclohexyl alanine side chain optimally fills the hydrophobic 
S2 subsite, while the leucine and t-butyl alanine side chains do not. A range of ring 
substituents were explored to enhance pharmacological activity. Compounds with a halogen 
at the meta position were particularly effective (compounds 16, 27, 29, 33). These 
observations are suggestive of the involvement of a halogen bond between the halogen and 
the C=O of Ala160, however, this could not be demonstrated with absolute certainty because 
of the partially disordered m-chlorobenzyl moiety.
In order to evaluate the specific interactions between the enzyme and the α-
hydroxyphosphonate inhibitors, inhibitor 17 was incubated with NV 3CLpro in Tris buffer, 
pH 8.0. Surprisingly, the enzyme-inhibitor complex formed corresponded to the complex 
formed between aldehyde 16 and 3CL protease. The formation of this complex indicates 
initial non-enzymatic (buffer)- or enzyme-catalyzed conversion of α-hydroxyphosphonate 
17 to the corresponding aldehyde 16, followed by the formation of a tetrahedral adduct with 
the active site cysteine (Cys139). Studies aimed at ascertaining the validity of this 
hypothesis are in progress. The ensemble of hydrogen bonding and hydrophobic interactions 
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in the enzyme-ligand complex are near identical to those observed with aldehyde inhibitor 
(I), where R1=cyclohexylmethyl, R1=H, X=CHO) (Figure 3).
An initial evaluation of selectivity was carried out using a panel of proteases and four 
representative inhibitors (16, 17, 29 and 30). As shown in Table 2, these compounds 
displayed minimal activity toward the proteases of the digestive and blood coagulation 
cascade systems. Selectivity was uniformly lower against the serine protease human 
neutrophil elastase (HNE).
Compound 16 was used to obtain a preliminary indication of in vivo efficacy. All 
compounds that were effective against NV in cell culture were also effective against MNV-1 
in the range 0.08 to 5 µM. Among them compound 16 was found to be the most effective 
with an EC50 value of 80 nM. It is noted that compound 16 was also most effective against 
NV (Table 1). In mice, treatment with compound 16 significantly reduced the virus titers in 
the small and large intestines at 3 days post virus infection by 42.12- and 7.98-fold, 
respectively, compared to the untreated control group (Figure 8). The overall virus titers in 
the small intestine were higher than those in the large intestine, and the reduction of viral 
titers was also greater in the small intestine than the large intestine.
In conclusion, these studies describe the optimization of the pharmacological activity and 
selectivity of dipeptidyl inhibitors of norovirus 3CL protease by employing iterative 
medicinal chemistry/SAR studies, X-ray crystallography, in vitro and cell-based screening, 
and in vivo efficacy studies. Importantly, these studies have identified lead compounds that 
show efficacy in the murine model of norovirus infection and, consequently, are suitable for 
conducting further pre-clinical studies.
Experimental Section
General
Reagents and dry solvents were purchased from various chemical suppliers (Aldrich, Acros 
Organics, Chem-Impex, TCI America, and Bachem) and were used as obtained. Silica gel 
(230–450 mesh) used for flash chromatography was purchased from Sorbent Technologies 
(Atlanta, GA). Thin layer chromatography was performed using Analtech silica gel plates. 
Visualization was accomplished using UV light and/or iodine. NMR spectra were recorded 
in CDCl3 or DMSO-d6 using a Varian XL-400 spectrometer. Melting points were recorded 
on a Mel-Temp apparatus and are uncorrected. High resolution mass spectrometry (HRMS) 
was performed at the University of Kansas Mass Spectrometry lab using an LCT Premier 
mass spectrometer (Waters, Milford, MA) equipped with a time of flight mass analyzer and 
an electrospray ion source. The purity of the compounds was established using HPLC and 
was >95%.
Synthesis of amino acid methyl esters 1. General procedure
To a 250 mL RB flask (oven dried and purged with nitrogen) was added absolute methanol 
(30 mL) and the solution was cooled to 0 °C in an ice bath while kept under a nitrogen 
atmosphere. Thionyl chloride (8 mL) was added to the cooled methanol with stirring, 
followed by the addition of the amino acid (100 mmol). The ice bath was replaced by a 
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water bath and the reaction mixture was heated to ~50 °C for 3 h with stirring. Removal of 
the solvent left a white residue which was washed with diethyl ether (250 mL) and collected 
by vacuum filtration to yield the amino acid methyl ester hydrochloride 1 as a white solid.
Synthesis of amino acid methyl ester isocyanates 2. General procedure
Amino acid methyl ester hydrochloride (100 mmol) was placed in a dry 500-mL RB flask 
and then dried overnight on the vacuum pump. The flask was flushed with nitrogen and dry 
dioxane (200 mL) was added followed by trichloromethyl chloroformate (29.67 g, 150 
mmol), and the reaction mixture was refluxed for 10 h. The solvent was removed on the 
rotary evaporator and the residue was vacuum distilled to yield pure isocyanate 2 as a 
colorless oil.
Synthesis of substituted benzyl carbamates 3. General procedure
A solution of substituted benzyl alcohol (20 mmol) in dry acetonitrile (15 mL) was treated 
with triethylamine (4.05 g, 40 mmol) followed by the amino acid methyl ester isocyanate 
(20 mmol). The resulting solution was refluxed for 2 h and then allowed to cool to room 
temperature. The solution was concentrated and the residue was taken up in ethyl acetate (75 
mL). The organic layer was washed with 5% HCl (2 × 20 mL) and brine (20 mL). The 
organic layer was dried over anhydrous sodium sulfate, filtered and concentrated, leaving a 
colorless oil (compound 3).
Synthesis of acids 4. General procedure
A solution of ester 3 (20 mmol) in tetrahydrofuran (30 mL) was treated with 1M LiOH (40 
mL). The reaction mixture was stirred for 3 h at room temperature and the disappearance of 
the ester was monitored by TLC. Most of the solvent was evaporated off and the residue was 
diluted with water (25 mL). The solution was acidified to pH ~3 using 5% hydrochloride 
acid (20 mL) and the aqueous layer was extracted with ethyl acetate (3 × 100 mL). The 
combined organic layers were dried over anhydrous sodium sulfate, filtered, and 
concentrated to yield compound 4 as a colorless oil.
Synthesis of compounds 5. General Procedure
To a solution of compound 4 (10 mmol) in dry DMF (20 mL) was added EDCI (2.40 g, 12.5 
mmol, 1.25 eq), HOBt (1.92 g, 12.5 mmol, 1.25 eq) and the mixture was stirred for 30 
minutes at room temperature. In a separate flask, a solution of deprotected glutamine 
surrogate 12 (2.23 g, 10 mmol) in DMF (15 mL) cooled to 0–5 °C was treated with 
diisopropylethylamine (DIEA) (9.5 g, 40 mmol, 4 eq), stirred for 30 minutes, and then added 
to the reaction mixture containing acid. The reaction mixture was stirred for 12 h while 
monitoring the reaction by TLC. The solvent was removed and the residue was partitioned 
between ethyl acetate (200 mL) and 10% citric acid (2 × 40 mL). The ethyl acetate layer was 
further washed with saturated aqueous NaHCO3 (40 mL), followed by saturated NaCl (50 
mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated 
to yield a yellow-colored oily product. Purification by flash chromatography yielded ester 5 
as a white solid.
Kankanamalage et al. Page 6













Synthesis of alcohols 6. General procedure
To a solution of ester 5 (5 mmol) in anhydrous THF (30 mL) was added lithium borohydride 
(2M in THF, 7.5 mL, 15 mmol) dropwise, followed by absolute ethyl alcohol (15 mL), and 
the reaction mixture was stirred at room temperature overnight. The reaction mixture was 
then acidified by adding 5% HCl and the pH adjusted to ~2. Removal of the solvent left a 
residue which was taken up in ethyl acetate (100 mL). The organic layer was washed with 
brine (25 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to yield 
compound 6 as a white solid.
Synthesis of aldehydes 7. General procedure
Compound 6 (5 mmol) was dissolved in anhydrous dichloromethane (50 mL) under a 
nitrogen atmosphere and cooled to 0°C. Dess-Martin periodinane reagent (3.18 g, 7.5 mmol, 
1.5 eq) was added to the reaction mixture with stirring. The ice bath was removed and the 
reaction mixture was stirred at room temperature for 3 h (monitoring by TLC indicated 
complete disappearance of the starting material). A solution of 10% aqueous sodium 
thiosulfate (20 mL) was added and the solution was stirred for another 15 minutes. The 
aqueous layer was removed and the organic layer was washed with 10% aqueous sodium 
thiosulfate (20 mL), followed by saturated aqueous sodium bicarbonate (2 × 20 mL), water 
(2 × 20 mL) and brine (20 mL). The organic layer was dried over anhydrous sodium sulfate, 
filtered and concentrated. The yellow residue was purified by flash chromatography (silica 
gel/methylene chloride/ethyl acetate/methanol) to yield a white solid 7.
2-Chlorobenzyl ((S)-3-cyclohexyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-
yl)propan-2-yl)amino)propan-2-yl)carbamate (13)—Yield (78%), mp 58–60 °C. 1H 
NMR (400 MHz, DMSO-d6) δ 9.41 (s, 1H), 8.47 – 8.52 (m, 1H), 7.57 – 7.69 (m, 1H), 7.44 – 
7.51 (m, 2H), 7.32 – 7.40 (m, 2H), 5.74 – 5.77 (m, 1H), 5.02 – 5.19 (m, 2H), 4.06 – 4.22 (m, 
2H), 3.00 – 3.17 (m, 2H), 2.19 – 2.31 (m, 1H), 2.08 – 2.17 (m, 1H), 1.84 – 1.94 (m, 1H), 
1.54 – 1.76 (m, 8H), 1.39 – 1.52 (m, 3H), 1.08 – 1.19 (m, 2H), 0.81 – 0.93 (m, 2H). HRMS 
(ESI) calcd for C24H32ClN3O5Na: [M+Na]+: 500.1928. Found: 500.1914.
3-Chlorobenzyl ((S)-3-cyclohexyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-
yl)propan-2-yl)amino)propan-2-yl)carbamate (16)—Yield (86%), mp 54–56 °C. 1H 
NMR (400 MHz, CDCl3) δ 9.46 (s, 1H), 8.35 (d, J = 5.47 Hz, 1H), 7.33 (br. s., 1H), 7.27 – 
7.31 (m, 1H), 7.22 – 7.27 (m, 1H), 7.16 – 7.21 (m, 1H), 6.36 – 6.49 (m, 1H), 5.60 (d, J = 
8.20 Hz, 1H), 5.05 (s, 2H), 4.17 – 4.41 (m, 2H), 3.15 – 3.38 (m, 2H), 2.24 – 2.50 (m, 2H), 
1.84 – 2.06 (m, 2H), 1.74 – 1.83 (m, 2H), 1.45 – 1.73 (m, 6H), 1.30 – 1.43 (m, 1H), 1.02 – 
1.27 (m, 3H), 0.76 – 1.01 (m, 2H). HRMS (ESI) calcd for C24H32ClN3O5Na: [M+Na]+: 
500.1928. Found: 500.1917.
3-Chlorobenzyl ((S)-1-cyclohexyl-2-oxo-2-(((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-
yl)propan-2-yl)amino)ethyl)carbamate (21)—Yield (81%), mp 51–53 °C. 1H NMR 
(400 MHz, CDCl3) δ 9.49 (s, 1H), 8.49 – 8.56 (m, 1H), 7.38 (br. s., 1H), 7.27 – 7.30 (m, 
2H), 7.23 (d, J = 4.30 Hz, 1H), 5.71 – 5.78 (m, 1H), 5.44 – 5.51 (m, 1H), 5.08 (d, J = 13.28 
Hz, 2H), 4.25 – 4.33 (m, 1H), 4.14 – 4.21 (m, 1H), 3.37 (d, J = 9.37 Hz, 2H), 2.36 – 2.52 
(m, 2H), 1.95 (d, J = 6.64 Hz, 1H), 1.88 (br. s., 1H), 1.76 (d, J = 10.94 Hz, 2H), 1.68 (br. s., 
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2H), 1.58 (s, 4H), 1.21 – 1.34 (m, 2H), 1.13 (d, J = 12.89 Hz, 2H). HRMS (ESI) calcd for 
C23H30ClN3O5Na: [M+Na]+: 486.1772. Found: 486.1758.
3-Chlorobenzyl ((S)-4-methyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-
yl)propan-2-yl)amino)pentan-2-yl)carbamate (22)—Yield (82%), mp 53–55 °C. 1H 
NMR (400 MHz, CDCl3) δ 9.45 (s, 1H), 8.51 – 8.54 (m, 1H), 7.90 – 7.94 (m, 1H), 7.36 – 
7.43 (m, 1H), 7.13 – 7.33 (m, 3H), 5.26 – 5.32 (m, 1H), 5.02 – 5.15 (m, 2H), 4.25 – 4.37 (m, 
2H), 3.29 – 3.41 (m, 2H), 2.39 – 2.47 (m, 1H), 1.83 – 1.99 (m, 2H), 1.66 – 1.78 (m, 3H), 
1.57 (m, 2H), 0.97 (d, J = 6.16 Hz, 6H).. HRMS (ESI) calcd for C21H28ClN3O5Na: [M
+Na]+: 460.1615. Found: 460.1611.
4-Chlorobenzyl ((S)-3-cyclohexyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-
yl)propan-2-yl)amino)propan-2-yl)carbamate (24)—Yield (67%), mp 56–58 °C. 1H 
NMR (400 MHz, CDCl3) δ 9.48 (s, 1H), 8.31 (d, J = 5.47 Hz, 1H), 7.27 – 7.35 (m, 4H), 6.01 
(br. s., 1H), 5.34 (d, J = 8.20 Hz, 1H), 5.03 – 5.11 (m, 2H), 4.28 – 4.39 (m, 2H), 3.35 (t, J = 
8.20 Hz, 2H), 2.35 – 2.51 (m, 2H), 1.90 – 1.98 (m, 1H), 1.79 – 1.90 (m, 2H), 1.60 – 1.76 (m, 
5H), 1.53 (ddd, J = 5.47, 8.98, 14.06 Hz, 1H), 1.23 – 1.30 (m, 2H), 1.08 – 1.22 (m, 2H), 0.81 
– 1.03 (m, 3H). HRMS (ESI) calcd for C24H32ClN3O5Na: [M+Na]+: 500.1928. Found: 
500.1917.
2-Fluorobenzyl ((S)-3-cyclohexyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-
yl)propan-2-yl)amino)propan-2-yl)carbamate (25)—Yield (81%), mp 61–63 °C. 1H 
NMR (400 MHz, CDCl3) δ 9.49 (s, 1H), 8.35 – 8.53 (m, 1H), 8.24 – 8.30 (m, 1H), 7.40 (t, J 
= 7.23 Hz, 1H), 7.27 – 7.34 (m, 1H), 7.10 – 7.17 (m, 1H), 7.05 (t, J = 9.18 Hz, 1H), 5.82 (br. 
s., 1H), 5.27 – 5.34 (m, 1H), 5.14 – 5.25 (m, 2H), 4.25 – 4.43 (m, 2H), 3.26 – 3.44 (m, 2H), 
2.31 – 2.57 (m, 2H), 1.93 – 2.00 (m, 2H), 1.79 – 1.91 (m, 2H), 1.47 – 1.76 (m, 5H), 1.38 (d, 
J = 2.73 Hz, 1H), 1.07 – 1.29 (m, 3H), 0.84 – 1.03 (m, 2H). HRMS (ESI) calcd for 
C24H32FN3O5Na: [M+Na]+: 484.2224. Found: 484.2214.
3-Fluorobenzyl ((S)-3-cyclohexyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-
yl)propan-2-yl)amino)propan-2-yl)carbamate (27)—Yield (66%), mp 53–55 °C. 1H 
NMR (400 MHz, CDCl3) δ 9.48 (s, 1H), 8.40 (d, J = 5.08 Hz, 1H), 7.27 – 7.35 (m, 1H), 7.06 
– 7.14 (m, 1H), 6.99 (dt, J = 2.34, 8.59 Hz, 2H), 5.97 (br s, 1H), 5.41 (d, J = 8.20 Hz, 1H), 
5.06 – 5.14 (m, 2H), 4.25 – 4.41 (m, 2H), 3.29 – 3.41 (m, 2H), 2.27 – 2.54 (m, 2H), 1.90 – 
2.00 (m, 1H), 1.79 – 1.89 (m, 2H), 1.60 – 1.78 (m, 6H), 1.48 – 1.58 (m, 1H), 1.32 – 1.46 (m, 
1H), 1.08 – 1.30 (m, 3H), 0.85 – 1.04 (m, 2H). HRMS (ESI) calcd for C24H32FN3O5Na: [M
+Na]+: 484.2224. Found: 484.2207.
3-Bromobenzyl ((S)-3-cyclohexyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-
yl)propan-2-yl)amino)propan-2-yl)carbamate (29)—Yield (83%), mp 52–55 °C. 1H 
NMR (400 MHz, CDCl3) δ 9.48 (s, 1H), 8.24 – 8.67 (m, 1H), 7.53 (br s, 1H), 7.35 – 7.47 
(m, 1H), 7.25 – 7.29 (m, 2H), 7.22 (d, J = 7.42 Hz, 1H), 5.66 – 5.74 (m, 1H), 5.08 (br s, 2H), 
4.23 – 4.40 (m, 2H), 3.36 (d, J = 8.59 Hz, 2H), 2.32 – 2.53 (m, 2H), 1.95 (br. s., 1H), 1.84 
(br. s., 2H), 1.69 (d, J = 9.37 Hz, 5H), 1.57 (br. s., 3H), 1.32 – 1.46 (m, 1H), 1.08 – 1.28 (m, 
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2H), 0.84 – 1.05 (m, 2H). HRMS (ESI) calcd for C24H32BrN3O5Na: [M+Na]+: 544.1423. 
Found: 544.1410.
3-Iodobenzyl ((S)-3-cyclohexyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-
yl)propan-2-yl)amino)propan-2-yl)carbamate (33)—Yield (80%), mp 56–58 °C. 1H 
NMR (400 MHz, CDCl3) δ 9.48 (s, 1H), 8.38 – 8.44 (m, 1H), 7.73 (br s, 1H), 7.64 (d, J = 
7.81 Hz, 1H), 7.31 (d, J = 7.81 Hz, 1H), 7.05 – 7.11 (m, 1H), 5.86 (br s, 1H), 5.34 (d, J = 
7.81 Hz, 1H), 5.05 (s, 2H), 4.27 – 4.39 (m, 2H), 3.31 – 3.40 (m, 2H), 2.32 – 2.53 (m, 2H), 
1.91 – 1.99 (m, 2H), 1.79 – 1.90 (m, 2H), 1.69 (d, J = 7.81 Hz, 6H), 1.47 – 1.58 (m, 1H), 
1.38 (br s, 1H), 1.09 – 1.29 (m, 2H), 0.84 – 1.04 (m, 2H). HRMS (ESI) calcd for 
C24H32IN3O5Na: [M+Na]+: 592.1284. Found: 592.1295.
2-Methoxybenzyl ((S)-3-cyclohexyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-
oxopyrrolidin-3-yl)propan-2-yl)amino)propan-2-yl)carbamate (35)—Yield (64%), 
mp 56–58 °C. 1H NMR (400 MHz, CDCl3) δ 9.49 (br. s., 1H), 8.16 – 8.24 (m, 1H), 7.30 – 
7.37 (m, 2H), 7.29 (s, 1H), 6.93 (t, J = 7.42 Hz, 1H), 6.88 (d, J = 8.20 Hz, 1H), 5.80 (br s, 
1H), 5.11 – 5.24 (m, 2H), 4.28 – 4.40 (m, 2H), 3.83 (s, 3H), 3.27 – 3.39 (m, 2H), 2.40 (d, J = 
12.89 Hz, 2H), 1.96 (br s, 2H), 1.78 – 1.90 (m, 2H), 1.64 – 1.76 (m, 4H), 1.60 (s, 1H), 1.53 
(dd, J = 4.10, 9.57 Hz, 1H), 1.39 (br s, 1H), 1.08 – 1.30 (m, 3H), 0.85 – 1.04 (m, 2H). 
HRMS (ESI) calcd for C25H35N3O6Na: [M+Na]+: 496.2424. Found: 496.2432.
3-Methoxybenzyl ((S)-3-cyclohexyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-
oxopyrrolidin-3-yl)propan-2-yl)amino)propan-2-yl)carbamate (36)—Yield (76%), 
mp 60–62 °C. 1H NMR (400 MHz, CDCl3) δ 9.48 (s, 1H), 8.32 (d, J = 5.95 Hz, 1H), 7.22 – 
7.26 (m, 1H), 6.88 – 6.95 (m, 2H), 6.84 (d, J = 8.24 Hz, 1H), 6.48 (br s, 1H), 5.56 (d, J = 
8.39 Hz, 1H), 5.08 (s, 2H), 4.22 – 4.44 (m, 2H), 3.80 (s, 3H), 3.24 – 3.36 (m, 2H), 2.29 – 
2.51 (m, 2H), 1.87 – 2.08 (m, 2H), 1.76 – 1.86 (m, 1H), 1.59 – 1.75 (m, 6H), 1.46 – 1.58 (m, 
1H), 1.38 (br. s., 1H), 1.06 – 1.28 (m, 3H), 0.82 – 1.04 (m, 2H). HRMS (ESI) calcd for 
C25H35N3O6Na: [M+Na]+: 496.2424. Found: 496.2418.
3-Cyanobenzyl ((S)-3-cyclohexyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-
yl)propan-2-yl)amino)propan-2-yl)carbamate (37)—Yield (73%), mp 58–60 °C. 1H 
NMR (400 MHz, CDCl3) δ 9.45 (s, 1H), 8.53 (d, J = 5.47 Hz, 1H), 7.65 – 7.76 (m, 2H), 7.54 
– 7.62 (m, 1H), 7.43 – 7.50 (m, 1H), 6.24 – 6.50 (m, 1H), 5.60 – 5.75 (m, 1H), 5.02 – 5.35 
(m, 2H), 4.45 – 4.56 (m, 1H), 4.24 – 4.41 (m, 1H), 3.18 – 3.43 (m, 2H), 2.29 – 2.59 (m, 2H), 
2.07 – 2.25 (m, 2H), 1.49 – 1.99 (m, 6H), 1.30 – 1.46 (m, 1H), 1.08 – 1.23 (m, 4H), 0.83 – 




(65%), mp 106–110 °C. 1H NMR (400 MHz, CDCl3) δ 9.52 (s, 1H), 9.41 – 9.46 (m, 1H), 
8.40 – 8.46 (m, 1H), 7.32 – 7.38 (m, 1H), 7.24 (br s, 1H), 7.22 (s, 1H), 7.20 (s, 1H), 6.92 – 
6.98 (m, 1H), 5.42 – 5.51 (m, 1H), 4.98 (s, 2H), 4.22 – 4.41 (m, 2H), 3.30 (d, J = 7.20 Hz, 
2H), 2.22 – 2.50 (m, 2H), 2.03 (s, 1H), 1.86 – 1.94 (m, 1H), 1.76 (d, J = 8.09 Hz, 3H), 1.56 
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– 1.72 (m, 4H), 1.48 (s, 9H), 1.30 – 1.40 (m, 1H), 1.04 – 1.25 (m, 4H), 0.91 (br s, 2H). 
HRMS (ESI) calcd for C29H42N4O7Na: [M+Na]+: 581.2951. Found: 581.2957.
3-Nitrobenzyl ((S)-3-cyclohexyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-
yl)propan-2-yl)amino)propan-2-yl)carbamate (39)—Yield (70%), mp 52–54 °C. 1H 
NMR (400 MHz, CDCl3) δ 9.45 (s, 1H), 8.67 (d, J = 5.08 Hz, 1H), 8.30 (s, 1H), 8.16 (d, J = 
8.20 Hz, 1H), 7.66 (d, J = 7.81 Hz, 1H), 7.50 – 7.55 (m, 1H), 5.85 (br s, 1H), 5.38 (d, J = 
8.20 Hz, 1H), 5.11 – 5.30 (m, 2H), 4.31 – 4.40 (m, 1H), 4.24 (d, J = 6.25 Hz, 1H), 3.37 (dd, 
J = 6.05, 8.79 Hz, 2H), 2.33 – 2.52 (m, 2H), 1.86 – 1.97 (m, 2H), 1.47 – 1.84 (m, 6H), 1.31 
– 1.44 (m, 2H), 1.06 – 1.28 (m, 3H), 0.82 – 1.04 (m, 3H). HRMS (ESI) calcd for 
C24H32N4O7Na: [M+Na]+: 511.2169. Found: 511.2153.
Benzyl ((S)-4-methyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-
yl)amino)pentan-2-yl)carbamate (40)—Yield (83%), mp 57–59 °C. 1H NMR (400 
MHz, CDCl3) δ 9.53 (br s, 1H), 8.32 – 8.45 (m, 1H), 7.32 – 7.46 (m, 5H), 5.78 – 5.85 (m, 
1H), 5.34 (br s, 1H), 5.09 – 5.18 (m, 2H), 4.35 (br s, 2H), 3.30 – 3.45 (m, 2H), 2.30 – 2.59 
(m, 2H), 1.99 (d, J = 6.64 Hz, 1H), 1.83 – 1.93 (m, 1H), 1.69 – 1.81 (m, 1H), 1.58 – 1.69 (m, 
2H), 1.23–1.30 (m, 1H), 0.94 (d, J= 6.15 Hz, 6H). HRMS (ESI) calcd for C21H29N3O5Na: 
[M+Na]+: 426.2005. Found: 426.1997.
Benzyl ((S)-3-cyclohexyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-
yl)propan-2-yl)amino)propan-2-yl)carbamate (43)—Yield (74%), mp 53–56 °C. 1H 
NMR (400 MHz, CDCl3) δ 9.48 (s, 1H), 8.31 (d, J = 5.86 Hz, 1H), 7.73 (br s, 1H), 7.34 (br 
s, 5H), 5.50 – 5.59 (m, 1H), 5.04 – 5.15 (m, 2H), 4.20 – 4.53 (m, 2H), 3.20 – 3.41 (m, 2H), 
2.23 – 2.51 (m, 2H), 1.88 – 2.03 (m, 1H), 1.74 – 1.86 (m, 2H), 1.66 (d, J = 5.86 Hz, 6H), 
1.45 – 1.58 (m, 1H), 1.30 – 1.43 (m, 1H), 1.18 (d, J = 16.12 Hz, 3H), 0.79 – 1.03 (m, 2H). 
HRMS (ESI) calcd for C24H33N3O5Na: [M+Na]+: 466.2318. Found: 466.2299.
Synthesis of α-Hydroxyphosphonates 8. General procedure
To a solution of diethylphosphite (135 mg, 1 mmol) in dry dichloromethane (3.5 mL) was 
added DIEA (129 mg, 1 mmol) followed by a solution of aldehyde 7 (1 mmol) in 
dichloromethane (5 mL). The reaction mixture was stirred at room temperature for 20 h. The 
reaction mixture was diluted with dichloromethane (100 mL) and washed with 5% HCl (2 × 
20 mL), and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate, 
filtered and concentrated, leaving a light yellow solid which was purified by flash 
chromatography to yield compound 8 as a white solid.
2-Chlorobenzyl ((2S)-3-cyclohexyl-1-(((2S)-1-(diethoxyphosphoryl)-1-
hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-1-oxopropan-2-
yl)carbamate (14)—Yield (79%), mp 103–106 °C. 1H NMR (400 MHz, CDCl3) δ 7.66 – 
7.71 (m, 1H), 7.41 (d, J = 3.12 Hz, 1H), 7.33 – 7.37 (m, 1H), 7.28 – 7.32 (m, 1H), 7.21 – 
7.26 (m, 3H), 5.49 – 5.57 (m, 1H), 5.15 – 5.24 (m, 2H), 4.06 – 4.21 (m, 4H), 3.97 – 4.04 (m, 
1H), 3.86 – 3.95 (m, 1H), 3.41 – 3.52 (m, 1H), 1.77 – 1.86 (m, 2H), 1.56 – 1.71 (m, 6H), 
1.50 – 1.56 (m, 1H), 1.25 – 1.37 (m, 7H), 1.23 (s, 2H), 1.17 (dt, J = 2.15, 7.13 Hz, 4H), 0.86 
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yl)carbamate (17)—Yield (81%), mp 58–61 °C. 1H NMR (400 MHz, CDCl3) δ 7.77 – 
7.83 (m, 1H), 7.30 – 7.38 (m, 1H), 7.24 – 7.29 (m, 2H), 7.16 – 7.23 (m, 1H), 6.39 – 6.48 (m, 
1H), 5.86 – 5.94 (m, 1H), 5.33 – 5.42 (m, 1H), 4.98 – 5.12 (m, 2H), 4.22 – 4.42 (m, 2H), 
4.07 – 4.20 (m, 4H), 3.91 – 4.01 (m, 1H), 3.17 – 3.35 (m, 2H), 2.30 – 2.47 (m, 2H), 2.10 – 
2.23 (m, 2H), 1.66 (d, J = 11.33 Hz, 6H), 1.41 – 1.54 (m, 2H), 1.28 – 1.36 (m, 6H), 1.05 – 




yl)carbamate (26)—Yield (73%), mp 98–101 °C. 1H NMR (400 MHz, DMSO-d6) δ 7.80 
(br s, 1H), 7.65 (d, J = 8.98 Hz, 1H), 7.49 – 7.57 (m, 1H), 7.33 – 7.48 (m, 2H), 7.14 – 7.25 
(m, 2H), 5.90 – 5.97 (m, 1H), 5.71 – 5.84 (m, 1H), 5.07 (d, J = 6.35 Hz, 2H), 3.95 – 4.09 (m, 
5H), 3.75 – 3.93 (m, 1H), 2.96 – 3.24 (m, 3H), 2.00 – 2.26 (m, 2H), 1.50 – 1.75 (m, 7H), 
1.36 – 1.47 (m, 2H), 1.19 – 1.33 (m, 6H), 1.01 – 1.15 (m, 3H), 0.84 (d, J = 7.91 Hz, 3H). 
HRMS (ESI) calcd for C28H43FN3O8PNa: [M+Na]+: 622.2670. Found: 622.2658.
3-Bromobenzyl ((2S)-3-cyclohexyl-1-(((2S)-1-(diethoxyphosphoryl)-1-
hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-1-oxopropan-2-
yl)carbamate (30)—Yield (78%), mp 48–52 °C. 1H NMR (400 MHz, CDCl3) δ 8.35 – 
8.40 (m, 1H), 7.46 (d, J = 3.32 Hz, 1H), 7.33 – 7.39 (m, 1H), 7.21 (br s, 1H), 7.11 – 7.18 (m, 
2H), 5.88 (s, 1H), 5.26 – 5.31 (m, 1H), 5.01 (d, J = 3.32 Hz, 2H), 4.02 – 4.15 (m, 6H), 3.27 
(d, J = 6.44 Hz, 3H), 1.88 (br. s., 1H), 1.76 (d, J = 9.37 Hz, 2H), 1.60 (br s, 7H), 1.46 (d, J = 
1.95 Hz, 1H), 1.23 – 1.34 (m, 6H), 1.19 (s, 1H), 0.98 – 1.16 (m, 3H), 0.75 – 0.96 (m, 3H). 
HRMS (ESI) calcd for C28H43BrN3O8PNa: [M+Na]+: 682.1869. Found: 682.1896.
Synthesis of bisulfite adducts 9. General procedure—To a solution of aldehyde 7 
(5 mmol) in dry ethyl acetate (20 mL) was added absolute ethanol (12 mL) with stirring, 
followed by a solution of sodium bisulfite (540 mg; 5 mmol) in water (5 mL). The reaction 
mixture was stirred for 3 h at 50 °C. The reaction mixture was allowed to cool to room 
temperature and then vacuum filtered. The solid was thoroughly washed with absolute 
ethanol and the filtrate was dried over anhydrous sodium sulfate, filtered, and concentrated 
to yield yellowish oil. The oily product was treated with ethyl ether (2 × 50 mL) to form 
white solid. The white solid was stirred with ethyl ether (30 mL) and ethyl acetate (15 mL) 




sulfonate (15)—Yield (60%), mp 128–132 °C. 1H NMR (400 MHz, CDCl3) δ 7.51 – 7.53 
(m, 1H), 7.40 – 7.45 (m, 1H), 7.35 – 7.39 (m, 1H), 7.26 (s, 3H), 6.99 – 7.00 (m, 1H), 5.18 – 
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5.29 (m, 2H), 3.68 – 3.78 (m, 2H), 3.48 (d, J = 7.03 Hz, 3H), 3.29 – 3.40 (m, 1H), 1.92 – 
1.98 (m, 1H), 1.80 – 1.91 (m, 2H), 1.71 (br s, 7H), 1.24 – 1.28 (m, 5H), 0.79 – 0.96 (m, 2H), 




sulfonate (18)—Yield (67%), mp 124–126 °C. 1H NMR (400 MHz, DMSO-d6) δ 7.66 (d, 
J = 8.98 Hz, 1H), 7.58 (dd, J = 9.18, 11.52 Hz, 1H), 7.49 (d, J = 8.20 Hz, 1H), 7.42 (d, J = 
4.30 Hz, 1H), 7.40 (d, J = 1.95 Hz, 1H), 7.30 – 7.39 (m, 2H), 5.41 (d, J = 5.86 Hz, 1H), 5.25 
(d, J = 5.86 Hz, 1H), 5.03 (s, 2H), 4.17 – 4.26 (m, 1H), 3.89 – 3.99 (m, 2H), 3.81 – 3.87 (m, 
1H), 3.10 (t, J = 9.96 Hz, 1H), 2.95 – 3.05 (m, 1H), 2.01 – 2.25 (m, 3H), 1.51 – 1.78 (m, 
6H), 1.37 – 1.48 (m, 1H), 1.28 (br s, 1H), 1.15 – 1.21 (m, 1H), 1.08 – 1.14 (m, 2H), 0.74 – 
0.94 (m, 2H). HRMS (ESI) calcd for C24H33ClN3O8S: [M-]: 558.1677. Found: 558.1656.
Sodium(2S)-2-((S)-2-((((3-bromobenzyl)oxy)carbonyl)amino)-3-
cyclohexylpropana mido)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propane-1-
sulfonate (31)—Yield (86%), mp 132–135 °C. 1H NMR (400 MHz, DMSO-d6) 0δ 7.68 
(d, J = 8.98 Hz, 1H), 7.60 (d, J = 9.37 Hz, 1H), 7.53 – 7.58 (m, 1H), 7.50 (d, J = 7.81 Hz, 
1H), 7.45 (d, J = 4.30 Hz, 1H), 7.29 – 7.41 (m, 2H), 5.54 (d, J = 5.47 Hz, 1H), 5.36 (d, J = 
5.08 Hz, 1H), 5.03 (s, 2H), 4.18 – 4.27 (m, 1H), 3.91 – 4.10 (m, 1H), 2.96 – 3.15 (m, 2H), 
2.05 – 2.23 (m, 2H), 1.89 – 2.05 (m, 1H), 1.49 – 1.75 (m, 6H), 1.38 – 1.47 (m, 1H), 1.23 – 
1.35 (m, 1H), 1.02 – 1.21 (m, 5H), 0.75 – 0.95 (m, 2H). HRMS (ESI) calcd for 
C24H33BrN3O8S: [M-]: 602.1172. Found: 602.1168.
Sodium (2S)-2-((S)-3-cyclohexyl-2-((((3-
iodobenzyl)oxy)carbonyl)amino)propane mido)-1-hydroxy-3-((S)-2-
oxopyrrolidin-3-yl)propane-1-sulfonate (34)—Yield (78%), mp 135–137 °C. 1H 
NMR (400 MHz, DMSO-d6) δ 8.48 – 8.52 (m, 1H), 7.73 (br s, 1H), 7.66 (d, J = 7.62 Hz, 
1H), 7.51 – 7.59 (m, 1H), 7.45 (d, J = 3.52 Hz, 1H), 7.36 (br s, 1H), 7.13 – 7.21 (m, 1H), 
5.45 – 5.52 (m, 1H), 5.28 – 5.35 (m, 1H), 4.92 – 5.14 (m, 2H), 4.13 – 4.29 (m, 1H), 3.88 – 
4.08 (m, 1H), 2.97 – 3.19 (m, 2H), 1.91 (s, 3H), 1.37 – 1.78 (m, 7H), 1.02 – 1.24 (m, 5H), 
0.73 – 0.97 (m, 3H). HRMS (ESI) calcd for C24H33IN3O8S: [M-]: 650.1033. Found: 
650.1019.
Sodium (2S)-2-((S)-2-(((benzyloxy)carbonyl)amino)-4-methylpentanamido)-1-
hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propane-1-sulfonate (41)—Yield (73%), mp 
109–113 °C. 1H NMR (400 MHz, DMSO-d6) δ 7.57 – 7.62 (m, 1H), 7.47 – 7.52 (m, 1H), 
7.26 – 7.40 (m, 5H), 5.47 – 5.51 (m, 1H), 5.31 – 5.36 (m, 1H), 4.96 – 5.05 (m, 3H), 4.19 – 
4.28 (m, 1H), 3.83 – 4.06 (m, 2H), 3.07 – 3.16 (m, 1H), 2.97 – 3.06 (m, 1H), 2.04 – 2.23 (m, 
2H), 1.71 – 1.81 (m, 1H), 1.52 – 1.68 (m, 2H), 1.39 – 1.50 (m, 2H), 0.85 (ddd, J = 3.03, 
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sulfonate (44)—Yield (78%), mp 131–133 °C. 1H NMR (400 MHz, DMSO-d6) δ 7.62 – 
7.69 (m, 1H), 7.43 – 7.51 (m, 1H), 7.27 – 7.40 (m, 5H), 5.82 – 5.86 (m, 1H), 5.52 (d, J = 
6.25 Hz, 1H), 5.36 (d, J = 5.96 Hz, 1H), 5.02 (s, 2H), 3.83 – 4.08 (m, 2H), 2.97 – 3.20 (m, 
3H), 1.86 – 2.25 (m, 3H), 1.51 – 1.82 (m, 6H), 1.37 – 1.48 (m, 2H), 1.29 (br s, 1H), 1.02 – 
1.22 (m, 3H), 0.75 – 0.94 (m, 2H). HRMS (ESI) calcd for C24H34N3O8S: [M-]: 524.2067. 
Found: 524.2045.
Synthesis of compound 10. General procedure
A solution of aldehyde 7 (5 mmol) in ethyl acetate (30 mL) kept at 0 °C was treated with 
acetic acid (0.34 g; 5.75 mmol) followed by cyclopropyl isocyanide (0.37 g; 5.5 mmol), and 
the reaction mixture was stirred at room temperature for 18 h. The solution was concentrated 
in vacuo and the residue was dissolved in methanol (30 mL) and treated with a solution of 
K2CO3 (1.72 g; 12.5 mmol) in water (25 mL). The reaction mixture was stirred at room 
temperature for 2 h. Methanol was evaporated off and the aqueous layer was extracted with 
ethyl acetate (3 × 100 mL). The combined organic layers were washed with 5% HCl (2 × 50 
mL) and brine (75 mL). The organic layer was dried over anhydrous sodium sulfate and the 
solvent was removed to yield compound 10 as a white solid. This was used in the next step 
without further purification.
Synthesis of α-ketoamides 11. General procedure
To a solution of compound 10 (5 mmol) in anhydrous dichloromethane (50 mL) cooled to 0 
°C and kept under a nitrogen atmosphere was added Dess-Martin periodinane reagent (3.18 
g, 7.5 mmol, 1.5 eq) with stirring. The ice bath was removed and the reaction mixture was 
stirred at room temperature for 3 h. The reaction was monitored by TLC until the starting 
material disappeared. A solution of 10% aqueous sodium thiosulfate (20 mL) was added and 
the solution was stirred for 15 minutes. The solution was poured into a separatory funnel and 
the aqueous layer was removed. The organic layer was washed with 10 % aqueous sodium 
thiosulfate (20 mL), followed by saturated aqueous sodium bicarbonate (2 × 20 mL), water 
(2 × 20 mL) and brine (20 mL). The organic layer was dried over anhydrous sodium sulfate, 
filtered and concentrated leaving a yellow solid which was purified by flash chromatography 
(silica gel/methylene chloride/ethyl acetate/methanol) to yield 11 as a white solid.
3-Chlorobenzyl ((S)-3-cyclohexyl-1-(((S)-4-(cyclopropylamino)-3,4-dioxo-1-
((S)-2-oxopyrrolidin-3-yl)butan-2-yl)amino)-1-oxopropan-2-yl)carbamate (19)—
Yield (88%), mp 135–138 °C. 1H NMR (400 MHz, CDCl3) δ 8.42 (br s, 1H), 7.36 (br s, 
1H), 7.27 – 7.29 (m, 2H), 7.19 – 7.24 (m, 2H), 6.97 (br s, 1H), 5.97 (br s, 1H), 5.08 (d, J = 
4.30 Hz, 2H), 4.24 – 4.42 (m, 2H), 3.27 – 3.40 (m, 2H), 2.76 (dd, J = 3.52, 7.42 Hz, 1H), 
2.35 – 2.60 (m, 2H), 2.07 (dd, J = 3.32, 5.27 Hz, 1H), 1.89 – 1.99 (m, 2H), 1.77 – 1.87 (m, 
2H), 1.59 – 1.75 (m, 4H), 1.43 – 1.56 (m, 1H), 1.38 (br s, 1H), 1.09 – 1.28 (m, 3H), 0.86 – 
1.04 (m, 2H), 0.81 – 0.85 (m, 2H), 0.56 – 0.66 (m, 2H). HRMS (ESI) calcd for 
C28H37ClN4O6Na: [M+Na]+: 583.2299. Found: 583.2293.
3-Chlorobenzyl ((S)-1-(((S)-4-(cyclopropylamino)-3,4-dioxo-1-((S)-2-
oxopyrrolidin-3-yl)butan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamate 
(23)—Yield (72%), mp 66–68 °C. 1H NMR (400 MHz, CDCl3) δ 8.40 (d, J = 5.47 Hz, 1H), 
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7.24 (br s, 1H), 7.16 – 7.22 (m, 1H), 7.11 (br s, 2H), 6.75 (br s, 1H), 5.63 – 5.75 (m, 1H), 
5.10 – 5.21 (m, 1H), 4.93 – 5.05 (m, 2H), 4.22 – 4.36 (m, 2H), 3.15 – 3.30 (m, 2H), 2.69 (d, 
J = 3.12 Hz, 1H), 2.39 – 2.51 (m, 1H), 2.31 (d, J = 3.91 Hz, 1H), 1.80 – 2.01 (m, 5H), 1.50 – 
1.72 (m, 3H), 1.38 – 1.49 (m, 2H), 0.86 (d, J = 4.69 Hz, 2H), 0.74 (d, J = 7.42 Hz, 2H), 0.54 
(br s, 2H). HRMS (ESI) calcd for C25H33ClN4O6Na: [M+Na]+: 543.1986. Found: 543.1989.
3-Fluorobenzyl ((S)-3-cyclohexyl-1-(((S)-4-(cyclopropylamino)-3,4-dioxo-1-
((S)-2-oxopyrrolidin-3-yl)butan-2-yl)amino)-1-oxopropan-2-yl)carbamate (28)—
Yield (74%), mp 95–98 °C. 1H NMR (400 MHz, CDCl3) δ 8.41 – 8.49 (m, 1H), 7.28 – 7.36 
(m, 2H), 7.25 (d, J = 2.34 Hz, 1H), 7.10 (t, J = 7.42 Hz, 2H), 6.90 – 7.02 (m, 1H), 5.83 (br s, 
1H), 5.04 – 5.13 (m, 2H), 4.25 – 4.39 (m, 2H), 3.36 (dd, J = 4.49, 8.79 Hz, 2H), 2.76 (dd, J 
= 3.52, 7.42 Hz, 1H), 2.51 – 2.61 (m, 1H), 2.39 – 2.50 (m, 1H), 2.06 – 2.14 (m, 1H), 1.94 (d, 
J = 10.94 Hz, 2H), 1.80 (br s, 1H), 1.58 – 1.74 (m, 6H), 1.48 (br s, 1H), 1.31 – 1.42 (m, 1H), 
1.07 – 1.29 (m, 3H), 0.79 – 1.03 (m, 3H), 0.61 (ddd, J = 1.56, 4.00, 5.76 Hz, 2H). HRMS 
(ESI) calcd for C28H37FN4O6Na: [M+Na]+: 567.2595. Found: 567.2592.
3-Bromobenzyl ((S)-3-cyclohexyl-1-(((S)-4-(cyclopropylamino)-3,4-dioxo-1-
((S)-2-oxopyrrolidin-3-yl)butan-2-yl)amino)-1-oxopropan-2-yl)carbamate (32)—
Yield (70%), mp 124–127 °C. 1H NMR (400 MHz, CDCl3) δ 8.39 – 8.45 (m, 1H), 7.52 (br 
s, 1H), 7.43 (d, J = 7.62 Hz, 1H), 7.27 (br s, 1H), 7.22 (d, J = 7.62 Hz, 2H), 6.90 – 6.95 (m, 
1H), 5.71 – 5.75 (m, 1H), 5.18 – 5.27 (m, 1H), 5.07 (s, 2H), 4.28 – 4.35 (m, 1H), 3.35 (dd, J 
= 4.10, 8.98 Hz, 3H), 2.72 – 2.81 (m, 2H), 2.06 – 2.15 (m, 2H), 1.86 – 2.01 (m, 2H), 1.69 (d, 
J = 10.94 Hz, 5H), 1.58 (s, 3H), 1.25 (s, 2H), 0.87 – 1.02 (m, 2H), 0.84 (d, J = 7.42 Hz, 2H), 
0.55 – 0.67 (m, 2H). HRMS (ESI) calcd for C28H37BrN4O6Na: [M+Na]+: 627.1794. Found: 
627.1791.
Benzyl ((S)-1-(((S)-4-(cyclopropylamino)-3,4-dioxo-1-((S)-2-oxopyrrolidin-3-
yl)butan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (42)—Yield (78%), 
mp 75–78 °C. 1H NMR (400 MHz, CDCl3) δ 8.43 (d, J = 5.68 Hz, 1H), 7.33 (s, 5H), 7.08 
(d, J = 3.48 Hz, 1H), 6.57 (s, 1H), 5.53 (d, J = 8.79 Hz, 1H), 5.19 – 5.26 (m, 1H), 5.08 (s, 
2H), 4.40 (dt, J = 5.49, 8.88 Hz, 1H), 3.22 – 3.36 (m, 2H), 2.71 – 2.80 (m, 1H), 2.48 – 2.58 
(m, 1H), 2.35 – 2.46 (m, 1H), 1.88 – 2.10 (m, 3H), 1.59 – 1.79 (m, 2H), 1.45 – 1.55 (m, 1H), 
0.95 (d, J = 6.41 Hz, 6H), 0.79 – 0.86 (m, 2H), 0.57 – 0.66 (m, 2H). HRMS (ESI) calcd for 
C25H34N4O6Na: [M+Na]+: 509.2376. Found: 509.2364.
Enzyme assays and inhibition studies against NV with 3CLpro and cell-based replicon 
system
These studies were carried out as described previously.13c
X-ray Crystallographic studies. Crystallization and Data Collection
Purified NV 3CLpro in 100 mM NaCl, 50 mM PBS pH 7.2, 1 mM DTT at a concentration 
of 10 mg/mL was used for preparation of the norovirus 3CL protease-compound 17 
complex. A stock solution of 100 mM compound 17 or 44 was prepared in DMSO and each 
NV 3CLpro:inhibitor complex was prepared by mixing 12 µL of 17 or 44 (3 mM) with 388 
µL (0.49 mM) of NV 3CLpro and incubating on ice for 1 h. The mixture was loaded onto a 
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Superdex 75 10/300 GL column equilibrated with 100 mM NaCl, 20 mM Tris pH 8.0 and 
the sample was concentrated to 8.0 mg/mL in a Vivaspin-20 (Vivaproducts, Inc.) 
concentrator for crystallization screening. All crystallization experiments were conducted 
Compact Jr. (Rigaku Reagents) sitting drop vapor diffusion plates at 20 °C using equal 
volumes of protein and the crystallization solution were equilibrated against 75 µL of the 
latter. Crystals of NV 3CLpro-ligand 17 that displayed a needle morphology were obtained 
overnight from the Proplex HT screen (Molecular Dimensions) condition D4 (20% (w/v) 
PEG 5000 MME, 100 mM Tris pH 7.5, 200 mM ammonium sulfate). Samples were 
transferred to a fresh drop composed of 80% crystallization solution and 20% PEG glycerol 
and stored in liquid nitrogen. Two crystal forms of the NV 3CLpro:44 complex that 
displayed a prismatic morphology were observed in 2 days from the Wizard 3 & 4 screen 
(Emerald Biosystems). The primitive hexagonal (NV 3CLpro:44-h) form was obtained from 
condition A1 (20% w/v PEG3350, 200 mM ammonium citrate) and a primitive 
orthorhombic (NV 3CLpro:44-o) from A10 (20% w/v PEG3350, 200 mM sodium 
thiocyanate). Samples were transferred to a fresh drop composed of 80% crystallization 
solution and 20% PEG 400 and stored in liquid nitrogen prior to data collection. X-ray 
diffraction data were collected at the Advanced Photon Source beamline 17-ID using a 
Dectris Pilatus 6M pixel array detector.
Structure Solution and Refinement
Intensities were integrated using XDS26–27 and the Laue class analysis and data scaling were 
performed with Aimless28 which suggested that the highest probability Laue class was 
6/mmm and possible space groups was P6122 or P6522 for NV 3CLpro, NV 3CLpro:17, and 
NV 3CLpro:44-h. The Matthew’s coefficient29 suggested that there was a single molecule in 
the asymmetric unit (Vm=2.8 Å3/Da, % solvent=56%). Structure solution was conducted by 
molecular replacement with Phaser30 using a previously determined structure of inhibitor 
bound NV 3CLpro (PDB: 3UR9)13c as the search model and all space groups with 622 point 
symmetry were tested. The top solution was obtained in the space group P6522 which was 
used from this point forward. NV 3CLpro:44-o was isomorphous with PDB 3UR9. Structure 
refinement using and manual model building were conducted with Phenix31 and Coot32 
respectively. Disordered side chains were truncated to the point for which electron density 
could be observed. Structure validation was conducted with Molprobity33 and figures were 
prepared using the CCP4MG package34.
Study with MNV.35
RAW264.7 cells, mouse macrophage cell line, were maintained in Dulbecco’s Minimum 
Essential Medium (DMEM) containing antibiotics of chlortetracycline (25 µg/ml), penicillin 
(250 U/ml), and streptomycin (250 µg/ml) in the presence of 2~5% fetal bovine serum. 
MNV-1 was obtained from H. Virgin at Washington University (St. Louis, MO). Antiviral 
activity of each compound against MNV-1 in cell culture was determined with RAW264.7 
cells. Each compound was dissolved in DMSO to make a 10 mM stock solution. The 
amount of DMSO in cell culture did not exceed 0.5%. The stock solution was serially 
diluted with cell culture media prior to addition to confluent monolayer of RAW264.7 cells 
in 24-well plates. Cells were immediately infected with virus at a multiplicity of infection 
(MOI) of 0.05 ~0.1. After further incubation of the cells at 37°C for 48 h, cells were frozen 
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and thawed and virus titers were determined by the 50% tissue culture infectious dose 
(TCID50) method. The 50% effective concentration (EC50) values were determined by 
GraphPad Prism (GraphPad Software, San Diego, CA) by nonlinear regression analyses of 
dose-response curves of the inhibition of virus replication against log inhibitor concentration 
(variable slope).
Animal experiments.36
The animal study was performed in accordance with a protocol approved by the Institutional 
Animal Care and Use Committee (IACUC) at Kansas State University. BALB/c mice were 
purchased from Charles River Lab (Wilmington, MA). Seven to eight week-old female 
BALB/c mice were inoculated intraperitoneally with MNV-1 at 2×106 TCID50/mouse. Mice 
were peritoneally given 50 µl of drug vehicle (10% EtOH and 90% PEG400) or compound 
16 (20 mg/kg/day) divided into two doses per day. Compound administration started 4 h 
prior to virus infection and continued daily until mice were euthanized. At 3 days post 
infection (dpi), mice were sacrificed and the small and large intestinal tracts were collected. 
The intestines were placed in PBS and the intestinal contents were gently removed by 
squeezing. The tissues were homogenized in PBS (5 or 3 mL for small and large intestines, 
respectively) and frozen at −70C until ready to use. Virus titers of the homogenized 
supernatant were determined by the TCID50 method and statistical analysis was performed 
on log-transformed TCID50 values using a two-tailed Student t-test (p<0.05). Fold changes 
in the geometric mean liver virus titers in each group were calculated by dividing virus titers 
in control group by the treated group.
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General structure of dipeptidyl inhibitor (I)
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Interaction of a cysteine protease (E-Cys-SH) with a peptidyl transition state inhibitor.
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Hydrogen bonding interactions between the inhibitor and chain B for NV 3CLpro:ligand 
(precursor aldehyde of inhibitor 44) Side chain residues are colored cyan, inhibitor is 
colored gray, and water molecules are represented as red spheres. Hydrogen bonds are 
represented as dashed lines and water mediated contacts as solid lines.
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Residues spanning Ala159-Lys162 located near the benzyl ring of precursor aldehyde of 
inhibitor 44.
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Fo – Fc map (green mesh) of precursor aldehyde derived from compound 17 bound to NV 
3CLpro contoured at 3σ.
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Hydrogen bond interactions between NV 3CLpro and precursor aldehyde derived from 
compound 17. Hydrogen bonds are represented as dashed lines and water mediated contacts 
are shown as solid lines.
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Surface representation of precursor aldehyde of compound 17 bound to NV 3CLpro. 
Neighboring residues of NV 3CLpro are colored yellow (nonpolar), white (weakly polar) 
and cyan (polar).
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Protease inhibitor suppresses norovirus replication in the intestinal tract in mice (effects of a 
3CLpro inhibitor treatment on murine norovirus titers in the intestinal tracts of mice). Balb/c 
mice were orally infected with MNV-1 at 2×106 TCID50 and intraperitoneally given 
compound 16 at 10 mg/kg twice daily with the first dose starting 4 hrs prior to virus 
infection. At 72 h post virus infection, the intestinal tract tissues were harvested and 
processed for determination for virus titers by the TCID50 assay. Mean and the standard 
error of the mean of virus titers in the small intestine (A) or large intestine (B) at 3 day post 
MNV-1 infection are shown. Each filled circle indicates a control mouse that was given drug 
vehicle and each empty box indicates a mouse given compound 16. Asterisk indicates 
P<0.01.
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Synthesis of inhibitors 13–44.
aCH3OH/SOCl2/45 °C/ 3h; bCCl3O(CO)Cl/ dioxane/ reflux/ 12h; c ArCH2OH/ TEA/ 
acetonitrile/ reflux/ 2h; d1M LiOH(aq)/ THF/ RT/ 3h; eEDCl/ HOBt/ DIEA/ DMF; f2M 
LiBH4/ THF/ CH3OH; gDess-Martin periodinane/ DCM; hDiethylphosphite/ DCM/ 
DIEA; iC2H5OH/ EtOAc/ HaHSO3; jEtOAc/ HOAc/ cyclopropyl isocyanide/ K2CO3(aq)/ 
CH3OH/ 18h
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Table 3
Crystallographic data for NV 3CLpro:inhibitor structures.
NV 3CLpro:17 NV 3CLpro:44-h NV 3CLpro:44-o
Data Collection
  Unit-cell parameters (Å, °) a=124.23, c=49.97 a=121.85, c=51.50 a=37.47 b=66.91 c=126.4
  Space group P6522 P6522 P212121
  Resolution (Å)1 45.32-1.85 46.28-1.60 45.94-1.45
(1.89-1.85) (1.63-1.60) (1.48-1.45)
  Wavelength (Å) 1.0000 1.0000 1.0000
  Temperature (K) 100 100 100
  Observed reflections 384,657 579,016 371,208
  Unique reflections 19,899 30,219 57,354
  <I/σ(I)>1 14.9 (2.4) 16.3 (2.0) 18.9 (1.8)
  Completeness (%)1 100 (100) 100 (100) 100 (100)
  Multiplicity1 19.3 (18.5) 19.2 (16.9) 6.5 (6.5)
  Rmerge (%)1, 2 19.7 (150.5) 16.6 (169.2) 4.7 (105.4)
  Rmeas (%)1, 4 20.3 (154.7) 17.0 (174.5) 5.1 (114.5)
  Rpim (%)1, 4 4.6 (35.8) 3.9 (42.3) 2.0 (44.4)
  CC1/2 1, 5 0.998 (0.763) 99.9 (71.1) 100 (63.5)
Refinement
  Resolution (Å) 1 45.32-1.85 36.85-1.60 35.65-1.45
  Reflections (working/test)1 18,907/968 28,660/1,530 54,369/2,905
  Rfactor / Rfree (%)1, 3 16.3/19.7 16.3/17.5 17.3/19.9




  Bond lengths (Å) 0.009 0.009 0.008
  Bond angles (°) 1.229 1.234 1.020
Average B-factor (Å2)
  All Atoms 21.1 17.2 24.3
  Protein 19.9 15.6 23.6
  Ligand 25.7 18.5 25.4
  Water 29.9 19.0 32.1
  Coordinate error 0.16 0.18 0.15
  (maximum likelihood) (Å)
Ramachandran Plot
  Most favored (%) 98.8 98.3 98.5
  Additionally allowed (%) 1.2 1.7 1.5
1
Values in parenthesis are for the highest resolution shell.
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2
Rmerge = ΣhkiΣi | Ii(hkl) - <I(hkl)> | / ΣhkiΣi Ii (hkl), where Ii(hkl) is the intensity measured for the i th reflection and <I(hkl)> is the average 
intensity of all reflections with indices hkl.
3
Rfacor = Σhkl | | Fobs(hkl) | – | Fcalc(hkl) | | / Σhkl | Fobs(hkl) |; Rfree is calculated in an identical manner using 5% of randomly selected 
reflections that were not included in the refinement.
4
Rmeas = redundancy-independent (multiplicity-weighted) Rmerge[28,37]. Rpim = precision-indicating (multiplicity-weighted) Rmerge[38, 39].
5
CC1/2 is the correlation coefficient of the mean intensities between two random half-sets of data [40,41].
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